Skip to main content
. 2021 Feb 22;22(4):2179. doi: 10.3390/ijms22042179

Figure 3.

Figure 3

Inhibition of PDR vitreous-induced activation of MIO-M1 cells. (A) qPCR analysis of NLRP3, IL1β, IL6, and IL8 expression in MIO-M1 cells treated with recombinant human VEGF-A or FGF2 for 4 and 8 h. Data are representative of 2 independent experiments in triplicate that gave similar results and are expressed as relative units in respect to control. * p < 0.05 and ** p < 0.01 vs. control or VEGF-A, one-way ANOVA. (B) qPCR analysis of NLRP3, IL1β, IL6, IL8, TNFα, MCP1, and VEGF-A expression in MIO-M1 cells treated with PDR vitreous for 4 h in the absence or in the presence of 10 µM ranibizumab, 100 nM BGJ398, 10 µM NSC12, 60 µM Boc2, or 10 µM hydrocortisone. Data are representative of 2 independent experiments in triplicate that gave similar results and are expressed as % in respect to PDR vitreous stimulation. * p < 0.05 and ** p < 0.01 vs. PDR vitreous, one-way ANOVA.